ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 749

Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology?

Cristina Arriens1, Sixia Chen2, David Karp3, Ramesh Saxena4, Joan T. Merrill1 and Judith A. James5, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, 4Nephrology Division, UT Southwestern Medical Center, Dallas, TX, 5Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus nephritis, Nephritis, outcomes and race/ethnicity, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus Nephritis (LN) usually presents within 5 years of SLE diagnosis, however the minority of patients with late-occurring nephritis are poorly characterized. Factors associated with high risk for early nephritis include male gender, Hispanic and African American race, and childhood-onset SLE (Jacobsen et. al. 1998, Seligman et. al. 2002). Since proliferative nephritis is a more aggressive class of nephritis than membranous and mesangial nephritis, we hypothesized that female gender, Caucasian race, adult-onset SLE, and membranous pathology would be associated with a later or more insidious onset of nephritis.

Methods: A single large urban medical center was the source for retrospective record review of patients who underwent kidney biopsy between 1999 and 2015. Patients with biopsy-proven LN were evaluated to determine whether gender, race, age at SLE diagnosis, age at first biopsy, or histopathologic classification were associated with the time (years) between SLE diagnosis and first renal biopsy.

Results: 630 patients were screened. After elimination of duplicates, those without initial biopsy, biopsy findings other than lupus nephritis, and unknown date of SLE diagnosis, 293 subjects had adequate data available for analysis. Those with late onset SLE, diagnosis after age 50 (n=15), were excluded from further analysis due to known differences in this subgroup. The remaining 278 patients had characteristics shown in Table 1. Twenty-nine percent of patients in this cohort developed nephritis more than 5 years after initial SLE diagnosis, including 50% of Asian, 37% of Caucasian, 33% of African American, and 20% of Hispanic LN patients. Multivariable linear regression identified greater age at first biopsy and race as the strongest predictors of time between SLE diagnosis and first renal biopsy. Hispanic patients were more likely to present with LN earlier in their course and Asian patients were more likely to present later, with African American and Caucasian groups between them. The model accounts for 27% of the variability in the time elapsed between diagnosis and biopsy. Histopathologic class did not make a significant contribution, and proliferative nephritis was noted in similar numbers of patients who developed LN after 5 years (73%) and those in the early presenting group (69%, p=0.6).

Conclusion: Surprisingly, more than a quarter of known LN patients at this large US center present after 5 years of SLE, higher than expected based on low numbers of late onset nephritis in other cohorts. This appears to be more common in Caucasian and Asian subgroups. Older patients are more likely to develop nephritis later, but aggressive histopathology is not less likely in later presentations. The data underscore the importance of remaining vigilant about nephritis risk in patients of diverse demographics five years and more after diagnosis with SLE.


Disclosure: C. Arriens, AstraZeneca, 5; S. Chen, None; D. Karp, None; R. Saxena, None; J. T. Merrill, BMS, GSK, 2,BMS, GSK, UCB, Questcor, EMD Serono, Amgen, Celgene, Pfizer, RemeGen, Exagen, MedImmune, Lilly, Janssen, Xencor, Sanofi, Neovacs, Immupharma, Astellas, Glenmark, ILToo, 5,Have given talks for BMS but not for Speaker’s bureau, 9; J. A. James, None.

To cite this abstract in AMA style:

Arriens C, Chen S, Karp D, Saxena R, Merrill JT, James JA. Is Lupus Nephritis Onset Delayed in Older Caucasian Females with Less Aggressive Pathology? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/is-lupus-nephritis-onset-delayed-in-older-caucasian-females-with-less-aggressive-pathology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-lupus-nephritis-onset-delayed-in-older-caucasian-females-with-less-aggressive-pathology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology